AZN.L - AstraZeneca PLC
| Previous Close | 6,793.00 |
| Open | 6,830.00 |
| Bid | 6,877.00 x 0 |
| Ask | 6,881.00 x 0 |
| Day's Range | 6,791.48 - 6,952.00 |
| 52 Week Range | 5,312.00 - 7,583.00 |
| Volume | 1,863,086 |
| Avg. Volume | 2,173,792 |
| Market Cap | 90.402B |
| Beta (3Y Monthly) | 1.05 |
| PE Ratio (TTM) | 40.25 |
| EPS (TTM) | 171.20 |
| Earnings Date | Oct 24, 2019 |
| Forward Dividend & Yield | 2.19 (3.22%) |
| Ex-Dividend Date | 2019-08-08 |
| 1y Target Est | 78.83 |
- Business Wire
FDA Grants Fast Track Designation for FARXIGA in Heart Failure
AstraZeneca today announced that the US Food and Drug Administration has granted Fast Track designation for the development of FARXIGA to reduce the risk of cardiovascular death or the worsening of heart failure in adults with heart failure with reduced ejection fraction or preserved ejection fraction .
- Reuters
AstraZeneca diabetes drug granted fast track status for heart failure treatment
The U.S. Food and Drug Administration (FDA) granted the status for development of the drug to reduce the risk of deadly heart attacks and disease progression in adults with the HFrEF and HFpEF subtypes of heart failure, the British drugmaker said on Monday. Farxiga, already approved as a treatment for type-2 diabetes, is part of the SGLT2-inhibitor class of antidiabetics that cause the kidneys to expel blood sugar from the body through urine.
- American City Business Journals
East Bay company eyes first drug approval after decade-long journey
The company has burned through $400 million, laid off employees and lost two Big Pharma partnerships, but now it is near an FDA drug approval for people with a debilitating bowel disorder.
- GuruFocus.com
Leaner Pfizer Positioned to Boost R&D Output
Company’s recent decisions will enable it to concentrate on building core business Continue reading...
- Simply Wall St.
Should You Buy AstraZeneca PLC (LON:AZN) For Its Dividend?
Today we'll take a closer look at AstraZeneca PLC (LON:AZN) from a dividend investor's perspective. Owning a strong...
- Business Wire
IMFINZI Is First Immunotherapy to Show Both Significant Survival Benefit and Improved, Durable Responses in Extensive-Stage Small Cell Lung Cancer
In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy backbone
- Reuters
CORRECTED-AstraZeneca's Imfinzi prolongs survival in aggressive lung cancer
AstraZeneca's cancer treatment Imfinzi has been shown to prolong survival in a particularly aggressive type of lung cancer by close to three months, as the British drugmaker holds its ground in a crowded field against rival immunotherapy drugs. Patients in a reference group on chemotherapy only lived a median 10.3 months in the so-called Caspian trial, it said. "There is a wide recognition that in small cell lung cancer there is very much a need for new therapies," said Dave Fredrickson, head of the company's oncology business.
- Barrons.com
Podcast: Why Big Pharma Is Betting on a New Biotech Therapy
Host Alex Eule is joined by Josh Nathan-Kasiz to talk about one of biotech’s most promising treatments, mRNA therapy.
- Motley Fool
Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class?
It’s rejected a pair of drugs in the last six months.
- American City Business Journals
5 things to know ahead of Viela Bio’s planned $150M IPO
It’s a pivotal moment for the MedImmune spinout, which has put the fate of its first prospective product in regulators' hands.
- Yahoo Finance
Companies to Watch: Roche gets more time for Spark deal, AstraZeneca shows promise in clinical trial, Snap get upgraded
Roche, Spark, AstraZeneca, Snap, Walmart and eBay are the companies to watch
- Benzinga
The Week Ahead In Biotech: Cardiology, Analyst Conferences In The Spotlight
The biotech space saw muted activity in the week ended Aug. 30. Among the notable news of the week: Amgen, Inc. (NASDAQ: AMGN )'s $13.4-billion deal to buy the psoriasis drug Otezla from Celgene Corporation ...
- American City Business Journals
Md. biotech files to go public with $150M offering
Gaithersburg-based Viela Bio Inc. has filed to begin trading publicly with a $150 million initial public offering, fast bringing the business full circle after its spinout from MedImmune in early 2018. The biotech applied to trade on the Nasdaq Global Market under the ticker symbol "VIE" and plans to offer a little more than 37 million shares to the public, including 393,780 shares of unvested restricted stock subject to repurchase.
- Benzinga
AstraZeneca Spin-Off Viela Bio Files For IPO
The IPO market, which has been in a lull in recent weeks, is likely to pick up steam just in time for a year-end push. Gaithersburg, Maryland-based Viela Bio, Inc., an AstraZeneca plc (NYSE: AZN ) spin-off, ...
- Business Wire
PT010 Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease
AstraZeneca today announced positive results from the Phase III ETHOS trial for triple-combination therapy PT010 in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
- Reuters
UPDATE 2-AstraZeneca respiratory business gets boost from 3-drug inhaler results
Prospects for AstraZeneca's respiratory treatments business improved on Wednesday as a three-drug inhaler was shown to ease smoker's lung and U.S. regulators granted its injectable asthma drug Fasenra special status for a rare lung condition. AstraZeneca said the late-stage ETHOS trial of triple-drug therapy Breztri Aerosphere, formerly known as PT010, helped patients suffering from chronic obstructive pulmonary disease (COPD), in a challenge to Glaxosmithkline’s Trelegy Ellipta.
- American City Business Journals
Viela Bio clears another hurdle to get rare disease drug to market
Gaithersburg’s Viela Bio Inc. has crossed another milepost in its race to get its first drug to market. The fast-moving biotech has submitted its formal application to the Food and Drug Administration to get approval to start marketing inebilizumab, its candidate for neuromyelitis optica spectrum disorder, a rare autoimmune disease that compromises the central nervous system. Under that timeline, pending approval, Viela could get the drug to patients by early next year.
- Business Wire
FDA Grants Fast Track Designation for FARXIGA in Chronic Kidney Disease
AstraZeneca today announced that the US Food and Drug Administration has granted Fast Track designation for the development of FARXIGA to delay the progression of renal failure and prevent cardiovascular and renal death in patients with chronic kidney disease .
- Reuters
UPDATE 1-U.S. FDA gives fast track status to AstraZeneca's diabetes drug Farxiga
AstraZeneca Plc said on Tuesday that the U.S. Food and Drug Administration has granted fast track status for the development of its diabetes drug Farxiga to prevent heart and kidney failure in patients with chronic kidney disease (CKD). Farxiga, one of AstraZeneca's top 10 drugs by sales, is part of the SGLT2-inhibitor class of antidiabetics that cause the kidneys to expel blood sugar from the body through urine.
- Benzinga
Bulls And Bears Of The Week: Chevron, Disney, Target And More
Benzinga has examined the prospects for many investor favorite stocks over the past week. It was another tough week for the markets, with the Dow Jones industrials and the S&P 500 dropping 2% or so and the Nasdaq more than 3% lower when all was said and done. The trade war with China ratcheted up again and commentary from Federal Reserve Chair Jerome Powell did not please the president (who apparently still wants to buy Greenland).
- Bloomberg
AstraZeneca's Executive VP Sees Upside, As China's Government Speeds Up New Drug Approval
Sep.09 -- AstraZeneca PLC is betting on sales of its new drug to outweigh that of off-patient ones in China over the next five years amid Chinese regulator's expedited approval of new therapies to meet unmet medical demands. Leon Wang, it's executive vice president overseeing international markets, spoke exclusively to Selina Wang on "Bloomberg Daybreak: Asia.
